The Board of Directors of Sopharma AD (the “Company”) notifies that for November 2012 sales revenues remained at the same level compared to the same period of 2011, including 1% increase of export sales and no changes in domestic sales.

During the first eleven months of this year Sopharma AD recorded an increase of sales revenues of 2%, including 9% decrease of domestic sales and 6% increase of export sales compared to the same period of 2011.

For the first six months of this year, revenues from sales decreased by 10% compared to the same period of 2015, including 3% decrease of domestic sales and a 15% decrease of export sales.

SOPHARMA AD hereby informs that from 7 July 2016 up to and including 13 July 2016 the Company bought 177 877 own shares representing 0.13% of the share capital of the Company, at a total value of 454 531.32 BGN on the Bulgarian Stock Exchange, the average price per share was 2.555 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 398 873, representing 4.01% of the share capital of the Company.

SOPHARMA AD hereby informs that from 14 July 2016 up to and including 20 July 2016 the Company bought 46 842 own shares representing 0.035% of the share capital of the Company, at a total value of 120 105.05 BGN on the Bulgarian Stock Exchange, the average price per share was 2.56 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 445 715, representing 4.04% of the share capital of the Company.

SOPHARMA AD hereby informs that the Company will commence the paying of dividends for 2015 on 3 August 2016 in accordance with a List of Entitled Persons as at 1 July 2016, prepared by the Central Depository.

Pursuant to the Regulations of the Central Depository AD the dividend will be paid out as follows: to shareholders with client accounts at an investment intermediary – through the investment intermediary, to shareholders without accounts at an investment intermediary – through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

The Board of Directors of Sopharma AD (the “Company”) notifies that in connection with the Christmas Holiday the results for December 2012 will be published on 10 January 2013.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 29 November 2012 up to and including 5 December 2012 the Company bought 50861 own shares representing 0.039% of the share capital of the Company, to the total value of BGN 114901.31 on the Bulgarian Stock Exchange. The average price per share was BGN 2.26.

SOPHARMA AD hereby informs that on 28 July 2016 the Company bought 2968 own shares representing 0.0022% of the share capital of the Company, at a total value of 8011.26 BGN on the Bulgarian Stock Exchange, the average price per share was 2.70 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 452 921, representing 4.05% of the share capital of the Company.

he Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 21 December 2012 Sopharma AD received a notification of disclosure of shareholdings from Financial Consulting Company regarding the selling of 999 840 shares. After this transaction the share of Financial Consulting Company in the capital of Sopharma AD decreased below 15% to 14, 56 %.

The date of registration of the transaction with the Central Depository AD is 20 December 2012.

For the first seven months of this year, revenues from sales decreased by 3% compared to the same period of 2015, including same level of domestic sales and a 4% decrease of export sales.

The good results in July led to reduced decrease of revenues for the period which was mainly due to the instability of the Russian market.